COFCO Biotechnology Co., Ltd. Class A

As of June 30, 2026, COFCO Biotechnology Co., Ltd. Class A carries a market capitalization of 7.89B, placing it among publicly traded companies globally. Its enterprise value stands at 11.06B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

COFCO Biotechnology Co., Ltd. Class A's next confirmed earnings release is scheduled for October 24, 2026.

As of June 30, 2026, COFCO Biotechnology Co., Ltd. Class A has 1.86B shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, COFCO Biotechnology Co., Ltd. Class A maintains a current ratio of 1.27, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, COFCO Biotechnology Co., Ltd. Class A recorded an income tax benefit of -16.92M rather than an expense, typically from losses, carryforwards, or the release of a tax provision.

As of the close on October 23, 2026, COFCO Biotechnology Co., Ltd. Class A's stock has declined approximately 23.72% over the past 52 weeks. The 50-day moving average sits at 5.12, while the 200-day moving average is 5.64.

As of June 30, 2026, COFCO Biotechnology Co., Ltd. Class A holds 2.13B in cash and equivalents against 4.91B in total debt, resulting in a net debt position of 2.56B. Total book value stands at 10.31B, with working capital of 1.53B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, COFCO Biotechnology Co., Ltd. Class A paid dividends of 0.04 per share.

COFCO Biotechnology Co., Ltd. Class A's most recent stock split took place on December 7, 2005 with a 1:2 split ratio.